Anita H Nadkarni

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5286436/publications.pdf

Version: 2024-02-01

66	959	566801	500791
papers	citations	15 h-index	28 g-index

67	67	67	1060
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Effect of Proinflammatory Cytokines (IL-6, TNF-Î±, and IL-1Î²) on Clinical Manifestations in Indian SLE Patients. Mediators of Inflammation, 2014, 2014, 1-8.	1.4	105
2	Matrix metalloproteinase and its drug targets therapy in solid and hematological malignancies: An overview. Mutation Research - Reviews in Mutation Research, 2013, 753, 7-23.	2.4	88
3	Response to hydroxyurea in Î² thalassemia major and intermedia: Experience in western India. Clinica Chimica Acta, 2009, 407, 10-15.	0.5	67
4	Hydroxyurea in sickle cell diseaseâ€"A study of clinico-pharmacological efficacy in the Indian haplotype. Blood Cells, Molecules, and Diseases, 2009, 42, 25-31.	0.6	58
5	Regional heterogeneity of Î²-thalassemia mutations in the multi ethnic Indian population. Blood Cells, Molecules, and Diseases, 2009, 42, 241-246.	0.6	56
6	Molecular pathogenesis and clinical variability of ?-thalassemia syndromes among Indians. American Journal of Hematology, 2001, 68, 75-80.	2.0	44
7	Prevalence and Molecular Characterization of Î±-Thalassemia Syndromes among Indians. Genetic Testing and Molecular Biomarkers, 2008, 12, 177-180.	1.7	33
8	Impact of Î² globin gene mutations on the clinical phenotype of Î² thalassemia in India. Blood Cells, Molecules, and Diseases, 2004, 33, 153-157.	0.6	29
9	Secretion and Expression of Matrix Metalloproteinase-2 and 9 from Bone Marrow Mononuclear Cells in Myelodysplastic Syndrome and Acute Myeloid Leukemia. Asian Pacific Journal of Cancer Prevention, 2016, 17, 1519-1529.	0.5	21
10	Molecular Characterization of ÎÎ²-Thalassemia and Hereditary Persistence of Fetal Hemoglobin in the Indian Population. Hemoglobin, 2008, 32, 425-433.	0.4	18
11	The phenotypic and molecular diversity of hemoglobinopathies in India: A review of 15Âyears at a referral center. International Journal of Laboratory Hematology, 2019, 41, 218-226.	0.7	18
12	Prenatal diagnosis of sickle syndromes in India: dilemmas in counselling. Prenatal Diagnosis, 2005, 25, 345-349.	1.1	17
13	Molecular Diversity of Hemoglobin H Disease in India. American Journal of Clinical Pathology, 2010, 133, 491-494.	0.4	17
14	Masking of a Î²-Thalassemia Determinant by a Novel Î´-Globin Gene Defect [Hb A₂-Saurashtra or Î´100(G2)Proâ†'Ser;HBD: c.301C>T] inCis. Hemoglobin, 2014, 38, 24-27.	0.4	17
15	Differential role of Kruppel like factor 1 (KLF1) gene in red blood cell disorders. Genomics, 2019, 111, 1771-1776.	1.3	17
16	Alpha Genotyping in a Heterogeneous Indian Population. American Journal of Hematology, 1996, 53, 149-150.	2.0	16
17	Diverse phenotypes and transfusion requirements due to interaction of Î²-thalassemias with triplicated Î±-globin genes. Annals of Hematology, 2015, 94, 1953-1958.	0.8	16
18	A functional SNP MCP-1 (â^'2518A/G) predispose to renal disorder in Indian Systemic Lupus Erythematosus patients. Cytokine, 2017, 96, 189-194.	1.4	16

#	Article	IF	Citations
19	Clinical and hematological presentation among Indian patients with common hemoglobin variants. Clinica Chimica Acta, 2014, 431, 46-51.	0.5	15
20	Does HbF induction by hydroxycarbamide work through <scp>MIR</scp>210 in sickle cell anaemia patients?. British Journal of Haematology, 2016, 173, 801-803.	1.2	15
21	Borderline HbA2 levels: Dilemma in diagnosis of beta-thalassemia carriers. Mutation Research - Reviews in Mutation Research, 2021, 788, 108387.	2.4	15
22	Potential of denaturing gradient gel electrophoresis for scanning of ?-thalassemia mutations in India. , 1999, 61, 120-125.		14
23	Impact of TNF-Î± and LTÎ± gene polymorphisms on genetic susceptibility in Indian SLE patients. Human Immunology, 2017, 78, 201-208.	1.2	14
24	Predisposition of IL-1Î² (-511 C/T) polymorphism to renal and hematologic disorders in Indian SLE patients. Gene, 2018, 641, 41-45.	1.0	14
25	The effect of UGT1A1 promoter polymorphism on bilirubin response to hydroxyurea therapy in hemoglobinopathies. Clinical Biochemistry, 2010, 43, 1329-1332.	0.8	12
26	Challenges in prenatal diagnosis of beta thalassaemia: couples with normal HbA₂ in one partner. Prenatal Diagnosis, 2015, 35, 1353-1357.	1.1	11
27	Mannose binding lectin (MBL) 2 gene polymorphism & its association with clinical manifestations in systemic lupus erythematosus (SLE) patients from western India. Indian Journal of Medical Research, 2015, 141, 199.	0.4	11
28	Hb D-AGRI [Î²9(A6)Ser Tyr;Î²121(GH4)Glu Gln]: A NEW INDIAN HEMOGLOBIN VARIANT WITH TWO AMINO ACID SUBSTITUTIONS IN THE SAME Î² CHAIN. Hemoglobin, 2001, 25, 317-321.	0.4	10
29	Impact of functional IL-18 polymorphisms on genetic predisposition and diverse clinical manifestations of the disease in Indian SLE patients. Lupus, 2019, 28, 545-554.	0.8	10
30	Compromising for carrier detection of beta thalassemia based on measurement of HbA2 levels in unusual cases. Clinica Chimica Acta, 2012, 413, 1705-1707.	0.5	9
31	Hematological and Molecular Analysis of Novel and Rare Î²-Thalassemia Mutations in the Indian Population. Hemoglobin, 2009, 33, 59-65.	0.4	8
32	Variable Presentation of HB H Disease Due to Homozygosity for the Rare Polyadenylation Signal A T^{Indian}(AATAAA>AATAâ€“ â€“) Mutation in Four Indian Families. Hemoglobin, 2013, 37, 277-284.	0.4	8
33	Hb E-Î²-Thalassemia in Five Indian States. Hemoglobin, 2016, 40, 310-315.	0.4	8
34	Significance of genetic modifiers of hemoglobinopathies leading towards precision medicine. Scientific Reports, 2021, 11, 20906.	1.6	8
35	Hb H Disease Due to Homozygosity for a Rare Î±2-Globin Variant, Hb Sallanches. Hemoglobin, 2010, 34, 45-48.	0.4	7
36	Variable haematological and clinical presentation of Î²-thalassaemia carriers and homozygotes with the Poly A (Tâ†’C) mutation in the Indian population. European Journal of Haematology, 2012, 89, 160-164.	1.1	7

#	Article	IF	Citations
37	Role of co-inherited Gilbert syndrome on hyperbilirubinemia in Indian beta thalassemia patients. Hematology, 2014, 19, 388-392.	0.7	7
38	Does the Novel KLF1 Gene Mutation Lead to a Delay in Fetal Hemoglobin Switch?. Annals of Human Genetics, 2017, 81, 125-128.	0.3	7
39	Insight of fetal to adult hemoglobin switch: Genetic modulators and therapeutic targets. Blood Reviews, 2021, 49, 100823.	2.8	7
40	Is the Poly A (T>C) Mutation a Causative Factor For Misdiagnosis in Second Trimester Prenatal Diagnosis of Î²-Thalassemia by Fetal Blood Analysis on High Performance Liquid Chromatography?. Hemoglobin, 2012, 36, 114-123.	0.4	6
41	The Prevalence of Factor V Leiden (G1691A) and Methylenetetrahydrofolate Reductase C677T Mutations in Sickle Cell Disease in Western India. Clinical and Applied Thrombosis/Hemostasis, 2015, 21, 186-189.	0.7	6
42	Role of polymorphisms in MMP-9 and TIMP-1 as biomarkers for susceptibility to systemic lupus erythematosus patients. Biomarkers in Medicine, 2019, 13, 33-43.	0.6	6
43	Role of MMP-2 and its inhibitor TIMP-2 as biomarkers for susceptibility to systemic lupus erythematosus. Biomarkers in Medicine, 2020, 14, 1109-1119.	0.6	6
44	Genotypic-phenotypic heterogeneity of ÎÎ²-thalassemia and hereditary persistence of fetal hemoglobin (HPFH) in India. Annals of Hematology, 2020, 99, 1475-1483.	0.8	6
45	Significance of borderline HbA2 levels in Î² thalassemia carrier screening. Scientific Reports, 2022, 12, 5414.	1.6	6
46	Prenatal diagnosis of HbEâ€Łepore and Hb Leporeâ€Î²â€thalassemia: the importance of accurate genotyping of the couple at risk. Prenatal Diagnosis, 2012, 32, 703-707.	1.1	5
47	Effect of a group of genetic markers around the 5â€² regulatory regions of the Î² globin gene cluster linked to high HbF on the clinical severity of Î² thalassemia. Blood Cells, Molecules, and Diseases, 2013, 50, 156-160.	0.6	5
48	Influence of single nucleotide polymorphisms in the BCL11A and HBS1L-MYB gene on the HbF levels and clinical severity of sickle cell anaemia patients. Annals of Hematology, 2016, 95, 1201-1203.	0.8	5
49	Prenatal Diagnosis of HbE-Î²-Thalassemia: Experience of a Center in Western India. Indian Journal of Hematology and Blood Transfusion, 2018, 34, 474-479.	0.3	5
50	Rare Î²- and Î´-Globin Gene Mutations in the Pathare Prabhus: Original Inhabitants of Mumbai, India. Hemoglobin, 2018, 42, 297-301.	0.4	5
51	Pleiotropic Roles of Metalloproteinases in Hematological Malignancies: an Update. Asian Pacific Journal of Cancer Prevention, 2016, 17, 3043-51.	0.5	5
52	Five Rare Î² Globin Chain Hemoglobin Variants in India. Indian Journal of Hematology and Blood Transfusion, 2016, 32, 282-286.	0.3	3
53	Synergistic effect of two Î² globin gene cluster mutations leading to the hereditary persistence of fetal hemoglobin (HPFH) phenotype. Molecular Biology Reports, 2017, 44, 413-417.	1.0	3
54	Cytokine genes multi-locus analysis reveals synergistic influence on genetic susceptibility in Indian SLE â€“ A multifactor-dimensionality reduction approach. Cytokine, 2020, 135, 155240.	1.4	3

#	Article	IF	Citations
55	HbD Punjab/HbQ India compound heterozygosity: An unusual association.. Mediterranean Journal of Hematology and Infectious Diseases, 2014, 6, e2014072.	0.5	2
56	Molecular characterization of weaker variants of A and B in Indian population â€“ The first report. Transfusion and Apheresis Science, 2014, 50, 118-122.	0.5	2
57	Red Cell Indices and Hemoglobin Profile of Newborn Babies with Both the Sickle Gene and Alpha Thalassaemia in Central India. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 109-113.	0.3	2
58	Clinical implications of IL-10 promoter polymorphisms on disease susceptibility in Indian SLE patients. Lupus, 2020, 29, 587-598.	0.8	2
59	The Changing Trends in Prenatal Diagnosis of Hemoglobinopathies in India: The Quest of a Single Center to Reduce the Burden of Disease over Three Decades. Hemoglobin, 2021, 45, 1-13.	0.4	2
60	Hemoglobin E and Pyrimidine 5â€² Nucleotidase Deficiency. Blood, 1997, 90, 1716-1716.	0.6	1
61	Fetal hemoglobin in sickle cell anemia. Blood Cells, Molecules, and Diseases, 2014, 52, 175.	0.6	1
62	Significance of heme oxygenase-1(HMOX1) gene on fetal hemoglobin induction in sickle cell anemia patients. Scientific Reports, 2020, 10, 18506.	1.6	1
63	Contribution of Genetic Factors in Variation of Clinical Severity Among Siblings with Homozygous Î²-Thalassemia in Two Indian Families. International Journal of Human Genetics, 2003, 3, 247-250.	0.1	0
64	Prevalence of globin gene modifiers encountered in fetuses during antenatal diagnosis of hemoglobinopathies. International Journal of Laboratory Hematology, 2020, 42, 482-491.	0.7	0
65	Hemoglobin E and Pyrimidine 5â€² Nucleotidase Deficiency. Blood, 1997, 90, 1716-1716.	0.6	0
66	Diagnostic challenges posed by a rare unstable hemoglobin variant Hb Southampton [HBB: c.320TÂâ†'ÂC] with pyrimidine 5â€² nucleotidase deficiency and the response to HU therapy. Blood Cells, Molecules, and Diseases, 2022, 96, 102667.	0.6	0